Paxlovid May Lower Long-term Risk
According to a new study, patients with long-term covid who received Paxlovid treatment appeared less likely to experience several vital symptoms related to long-term covid. It’s an oral antiviral that has proven to be highly effective in preventing hospitalization and death among elderly and at-risk patients.
The study, which used databases from the Department of Veterans Affairs, looked at almost 50,000 people who tested positive but did not take Paxlovid and more than 9,000 people who took the medication. In 10 of the 12 symptoms that were examined, including the frequent complaints of lingering fatigue and brain fog, there was an approximate 25% reduction. Whether a person had received a vaccination or previously contracted an infection had no impact on the outcome.
Akiko Iwasaki, a professor of immunobiology and molecular, cellular, and developmental biology at Yale University, emphasized the significance of this study. Its effects on public health are still very relevant today.
